GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eagle Pharmaceuticals Inc (FRA:1E6) » Definitions » Cyclically Adjusted PB Ratio

Eagle Pharmaceuticals (FRA:1E6) Cyclically Adjusted PB Ratio : 0.29 (As of Jun. 12, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Eagle Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-06-12), Eagle Pharmaceuticals's current share price is €3.24. Eagle Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 was €11.35. Eagle Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.29.

The historical rank and industry rank for Eagle Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:1E6' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.28   Med: 1.6   Max: 4.4
Current: 0.3

During the past years, Eagle Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 4.40. The lowest was 0.28. And the median was 1.60.

FRA:1E6's Cyclically Adjusted PB Ratio is ranked better than
91.46% of 749 companies
in the Drug Manufacturers industry
Industry Median: 1.89 vs FRA:1E6: 0.30

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Eagle Pharmaceuticals's adjusted book value per share data for the three months ended in Jun. 2023 was €17.765. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €11.35 for the trailing ten years ended in Jun. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eagle Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Eagle Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eagle Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Eagle Pharmaceuticals Annual Data
Trend Sep13 Sep14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 2.52

Eagle Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.19 2.32 2.52 2.37 1.59

Competitive Comparison of Eagle Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Eagle Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eagle Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eagle Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Eagle Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Eagle Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Eagle Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=3.24/11.35
=0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eagle Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 is calculated as:

For example, Eagle Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2023 was:

Adj_Book=Book Value per Share/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=17.765/128.7287*128.7287
=17.765

Current CPI (Jun. 2023) = 128.7287.

Eagle Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201309 -4.725 98.790 -6.157
201312 0.041 98.326 0.054
201403 2.304 99.695 2.975
201406 2.200 100.560 2.816
201409 1.830 100.428 2.346
201412 1.612 99.070 2.095
201503 6.130 99.621 7.921
201506 5.512 100.684 7.047
201509 5.008 100.392 6.422
201512 5.304 99.792 6.842
201603 5.302 100.470 6.793
201606 6.138 101.688 7.770
201609 6.091 101.861 7.698
201612 9.355 101.863 11.822
201703 10.227 102.862 12.799
201706 9.702 103.349 12.085
201709 9.620 104.136 11.892
201712 10.195 104.011 12.618
201803 9.763 105.290 11.936
201806 10.568 106.317 12.796
201809 11.147 106.507 13.473
201812 10.156 105.998 12.334
201903 11.141 107.251 13.372
201906 11.169 108.070 13.304
201909 11.675 108.329 13.873
201912 11.831 108.420 14.047
202003 12.043 108.902 14.236
202006 12.008 108.767 14.212
202009 11.258 109.815 13.197
202012 11.710 109.897 13.717
202103 12.210 111.754 14.065
202106 12.348 114.631 13.867
202109 12.167 115.734 13.533
202112 12.208 117.630 13.360
202203 15.444 121.301 16.390
202206 16.965 125.017 17.469
202209 17.986 125.227 18.489
202212 16.938 125.222 17.412
202303 17.335 127.348 17.523
202306 17.765 128.729 17.765

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eagle Pharmaceuticals  (FRA:1E6) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Eagle Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Eagle Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eagle Pharmaceuticals (FRA:1E6) Business Description

Traded in Other Exchanges
Address
50 Tice Boulevard, Suite 315, Woodcliff Lake, NJ, USA, 07677
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.

Eagle Pharmaceuticals (FRA:1E6) Headlines

No Headlines